Illumina, Inc. (NASDAQ:ILMN) Stock Position Reduced by JGP Global Gestao de Recursos Ltda.

JGP Global Gestao de Recursos Ltda. cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 82.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 580 shares of the life sciences company’s stock after selling 2,644 shares during the period. JGP Global Gestao de Recursos Ltda.’s holdings in Illumina were worth $214,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ILMN. Massmutual Trust Co. FSB ADV grew its position in Illumina by 83.0% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 39 shares in the last quarter. Strategy Asset Managers LLC bought a new stake in Illumina in the first quarter worth approximately $26,000. Financial Advocates Investment Management grew its position in Illumina by 1,430.0% in the fourth quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 572 shares in the last quarter. C J Advisory Inc bought a new stake in Illumina in the first quarter worth approximately $29,000. Finally, Valeo Financial Advisors LLC grew its position in Illumina by 130.0% in the first quarter. Valeo Financial Advisors LLC now owns 115 shares of the life sciences company’s stock worth $36,000 after acquiring an additional 65 shares in the last quarter. 90.48% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have commented on ILMN. BidaskClub downgraded shares of Weyco Group from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 13th. Deutsche Bank boosted their target price on shares of Spirit Airlines from $75.00 to $79.00 and gave the stock a “buy” rating in a research report on Friday, July 12th. Bank of America set a $80.00 target price on shares of Colgate-Palmolive and gave the stock a “buy” rating in a research report on Friday, July 12th. Wolfe Research began coverage on shares of Waters in a research report on Thursday, May 30th. They issued an “underperform” rating for the company. Finally, Canaccord Genuity boosted their target price on shares of Hiscox from GBX 1,580 ($20.65) to GBX 1,600 ($20.91) and gave the stock a “sell” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company’s stock. Illumina currently has an average rating of “Buy” and a consensus target price of $332.77.

In other news, SVP Charles Dadswell sold 124 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $371.29, for a total value of $46,039.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mostafa Ronaghi sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $305.49, for a total transaction of $3,054,900.00. Following the completion of the sale, the senior vice president now owns 87,414 shares of the company’s stock, valued at $26,704,102.86. The disclosure for this sale can be found here. Insiders sold 61,167 shares of company stock valued at $19,899,477 over the last 90 days. 0.38% of the stock is owned by corporate insiders.

Shares of Illumina stock traded up $2.65 on Wednesday, reaching $302.61. The stock had a trading volume of 21,444 shares, compared to its average volume of 1,559,709. The business has a 50-day moving average price of $337.89. The company has a current ratio of 3.66, a quick ratio of 3.33 and a debt-to-equity ratio of 0.27. Illumina, Inc. has a fifty-two week low of $268.62 and a fifty-two week high of $380.76. The company has a market capitalization of $43.87 billion, a PE ratio of 52.93, a P/E/G ratio of 2.62 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.03. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The business had revenue of $838.00 million during the quarter, compared to analysts’ expectations of $835.12 million. During the same period in the previous year, the company earned $1.43 earnings per share. Illumina’s revenue for the quarter was up 1.0% on a year-over-year basis. On average, sell-side analysts forecast that Illumina, Inc. will post 6.34 earnings per share for the current year.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

See Also: What is quantitative easing?

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.